# A Phase I/II Study of FG-M108 Plus FG-B901 in Advanced CLDN18.2-Positive Solid Tumors

> **NCT07704866** · PHASE1,PHASE2 · NOT_YET_RECRUITING · sponsor: **FutureGen Biopharmaceutical (Beijing) Co., Ltd** · enrollment: 120 (estimated)

## Conditions studied

- Claudin 18.2
- Solid Tumor Malignancies

## Interventions

- **DRUG:** FG-B901
- **DRUG:** FG-B901
- **DRUG:** FG-M108

## Key facts

- **NCT ID:** NCT07704866
- **Lead sponsor:** FutureGen Biopharmaceutical (Beijing) Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-07-30
- **Primary completion:** 2028-08-31
- **Final completion:** 2029-02-28
- **Target enrollment:** 120 (ESTIMATED)
- **Last updated:** 2026-07-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07704866

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07704866, "A Phase I/II Study of FG-M108 Plus FG-B901 in Advanced CLDN18.2-Positive Solid Tumors". Retrieved via MORVS 2026-10-21 from https://api.morvs.ai/clinical/NCT07704866. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*